COVID-19 – Therapeutic controversies. The case of ibuprofen
| Autor: | Camil-Eugen Vari, Bianca-Eugenia Ősz, George Jîtcă, Alexandra Groşan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Romanian Journal of Pharmaceutical Practice, Vol 13, Iss 2, Pp 53-56 (2020) |
| ISSN: | 2069-6671 2066-5563 |
| Popis: | Shortly after the declaration of the SARS-CoV-2 infection pandemic by the World Health Organization (WHO), a controversy erupted over the worsening of the disease by NSAIDs, particularly ibuprofen. The premise of this concern was the increase in expression of the ACE2 enzyme in epithelial cells by chronic treatment with ibuprofen; this enzyme is used as a gateway by the virus. Reality and clinical experience have refuted this hypothesis, a fact certified by the regulatory authorities in the field of medicine (EMA – European Medicines Agency, FDA – Food and Drug Administration). Clinical experience suggests exactly the opposite, and the possible protective effect against acute respiratory distress syndrome (ARDS) is currently being investigated in an ongoing clinical study, which is expected to be completed in May 2021. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|